This is a working overview of HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Sunak refuses to rule out a general election in July following speculation of a summer election. 29 April – 2024 Scottish government crisis: First Minister, Humza Yousaf, announces he will resign as both leader of the SNP and first minister of Scotland when his successor is chosen. The UK government launches a 12 week consultation process on changes to Personal Independence Payment benefits. MPs debates assisted dying after a petition started by Dame Esther Rantzen was signed by 200,000 people, triggering a parliamentary debate. SDLP Councillor Lilian Seenoi-Barr is set to become Northern Ireland's first black mayor after being selected as the next first citizen of Derry City and Strabane District Council. 30 April – Officials at Holyrood confirm that Labour's motion of no confidence in the Scottish Government will be voted on by MSPs the next day. Former England cricketer Monty Panesar is announced as the Workers Party of Britain candidate for Ealing Southall.
C.D.E. See: #Certified diabetes educator. C-peptide A substance the pancreas releases into the bloodstream in equal amounts to insulin. While being stored in pancreatic beta cells, proinsulin includes both insulin and C-peptide, which is freed before insulin secretion into the blood. Currently, since pharmaceutical insulin does not contain C-peptide, a C-peptide level test will show how much insulin the body is making. Insulin is prepared as two insulin molecules linked by a c-peptide. When insulin is secreted, C-peptide is released as well. It has in recent years been shown to have hormone properties, so far chiefly in connection with arterial vessel muscle tone. It has been shown to ameliorate some diabetic complications, such as neuropathy and microvascular damage. C-peptide varies much more between animal species than does insulin itself. Calcium channel blocker Calcium ions are used in many cells, including beta cells, as a signaling mechanism. Since it does not ordinarily pass through cell membranes, protein pores in cell membranes are used to provide a channel through which it can be 'pumped' – an activity which requires energy if done against a concentration gradient. A Ca+ channel blocker is a drug which interferes with the operation of (some?) such channels. They have widespread effects, since Ca+ is used for many purposes in assorted tissues.
A 2004 essay on the relation between car colour and safety stated that no previous studies had been scientifically conclusive. Since then, a Swedish study found that pink cars are involved in the fewest and black cars are involved in the most crashes (Land transport NZ 2005). In Auckland New Zealand, a study found that there was a significantly lower rate of serious injury in silver cars, with higher rates in brown, black, and green cars. The Vehicle Colour Study, conducted by Monash University Accident Research Centre (MUARC) and published in 2007, analysed 855,258 crashes that occurring between 1987 and 2004 in the Australian states of Victoria and Western Australia that resulted in injury or in a vehicle being towed away. The study analysed risk by light condition. It found that in daylight, black cars were 12% more likely than white to be involved in a collision, followed by grey cars at 11%, silver cars at 10%, and red and blue cars at 7%, with no other colours found to be significantly more or less risky than white. At dawn or dusk, the risk ratio for black cars jumped to 47% more likely than white, and that for silver cars to 15%. In the hours of darkness, only red and silver cars were found to be significantly more risky than white, by 10% and 8% respectively.
Within the field of molecular biology, a protein-fragment complementation assay, or PCA, is a method for the identification and quantification of protein–protein interactions. In the PCA, the proteins of interest ("bait" and "prey") are each covalently linked to fragments of a third protein (e.g. DHFR, which acts as a "reporter"). Interaction between the bait and the prey proteins brings the fragments of the reporter protein in close proximity to allow them to form a functional reporter protein whose activity can be measured. This principle can be applied to many different reporter proteins and is also the basis for the yeast two-hybrid system, an archetypical PCA assay.
Sources: en.wikipedia.org
In July 2008, the whole site was rebranded under the Edge title, as that was the senior of the two brands. In May 2014 it was reported that Future intended to close the websites of Edge, Computer and Video Games and their other videogame publications; in December 2014, it was confirmed that the C&VG website would close and its content would instead be published at GamesRadar, and in January 2015, it was announced that the same would happen to the Edge website. Between 2015 and 2018, Edge articles were occasionally republished on Kotaku UK. Edge has been redesigned three times since the magazine launched. The first redesign occurred in 1999; the second in 2004; and the third in 2011. The first redesign altered the magazine's dimensions to be wider than the original shape. The latest design changes the magazine's physical dimensions for the second time, and introduces a higher quality of paper stock than was previously used.
Following a decentralized strategy, Iranian units responded with a series of missile and drone attacks against Israel and US military bases in the Middle East, attacked US allies in the Middle East, as well as blocked the Strait of Hormuz and subsequently claimed sovereignty over it in late March. Following the strikes on their territory, the United Arab Emirates, Saudi Arabia, Kuwait, and Bahrain also attacked Iran and skirmished with its Iraqi non-state allies. Two days after Khamenei's assassination, fighting resumed between Hezbollah and Israel. Israel began occupying southern Lebanon in March. An escalation of the Yemeni civil war by the Iran-backed Houthi forces in September started the Strait of Bab al-Mandab crisis. The war has resulted in thousands of civilian and military casualties. The economic impact of the war included the largest supply disruption of the global oil market, disruptions of the natural gas, fertilizer, aviation, and tourism industries, and volatility in financial markets. As of September 2026, the US Department of Defense estimated that the war had so far cost $43.6 billion. The secretary-general of the United Nations and several countries condemned the US–Israeli strikes, while the United Nations Security Council passed a resolution condemning Iran's retaliatory strikes on Gulf states. A two-week ceasefire beginning on 8 April came under strain after Iran responded to Israeli attacks on Lebanon by resuming its blockade. After the failure of the Islamabad Talks on 12–13 April, the US imposed its own naval blockade.
== US–EU trade war == In response to Operation Arctic Endurance and European countries' refusal to support his annexation of Greenland, Trump threatened to increase tariffs against several EU and NATO members, reigniting concerns of a US-EU trade war. Trump said he would impose tariffs on any trading partner that did not support American annexation of Greenland. In January 2026, he threatened Denmark, Norway, Sweden, France, Germany, the United Kingdom, the Netherlands, and Finland with tariffs of up to 25% tariffs until they supported his takeover of Greenland, stating that they had "journeyed to Greenland, for purposes unknown. This is a very dangerous situation for the Safety, Security, and Survival of our Planet". On 21 January, Trump announced that he would not impose the tariffs, having agreed to a deal with NATO secretary general Mark Rutte.
Sources: en.wikipedia.org
AlphaFold's predicted structures are widely used in biological research, though the precise scale of that use is difficult to measure. More than 40% of protein-structure papers published in 2023 in Cell, Nature, and Science cited AlphaFold 2. A 2024 bibliometric analysis of the Web of Science database identified 1,680 peer-reviewed papers referencing AlphaFold published between January 2019 and May 2024. Measures of this kind rely on authors citing the AlphaFold papers when they use the tool, a convention encouraged but not enforced by the maintainers of the AlphaFold Protein Structure Database. Attempts to validate these counts against the full text of papers suggest that citations to foundational AlphaFold papers can both overstate and understate how widely the tool is used. In an analysis of about 8,900 papers in the PubMed Central Open Access corpus that mentioned AlphaFold, roughly 30% cited none of three foundational AlphaFold papers, while only about half of the papers citing at least one of those three mentioned AlphaFold anywhere in their text. A smaller manual check of 100 papers from a curated protein-literature database found a similar shortfall, with fewer than half of those mentioning AlphaFold including a formal citation.
When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.
== Licensing == A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5–100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period. The FDA approved saxagliptin with brand name Onglyza on July 31, 2009. Saxagliptin was licensed for use throughout the European Union by the European Medicines Agency on December 1, 2009. Bristol-Myers Squibb announced on 27 December 2006 that Otsuka Pharmaceutical Co. has been granted exclusive rights to develop and commercialize the compound in Japan. Under the licensing agreement, Otsuka will be responsible for all development costs, but Bristol-Myers Squibb retains rights to co-promote saxagliptin with Otsuka in Japan. Further, on 11 January 2007 it was announced that Bristol-Myers Squibb and AstraZeneca would work together to complete development of the drug and in subsequent marketing.
These plans had been made some time ago." Russian military intelligence source alleged that the United States knew the date when the war in South Ossetia would begin because the United States military delegation cancelled the visit to Russia, which was scheduled on 10-14 August, on August 1 and cited the absence of the Russian permit for the flight. In late August 2008, Batu Kutelia, the deputy defence minister told the Financial Times that the decision to take Tskhinvali was made in spite of the fact that Georgia did not have enough anti-tank and air defences because "At some point there was no choice." He also said that Georgian authorities and military did not expect Russia to use a large-scale force against Georgia. In August 2008, Steven Pifer, former Ambassador to Ukraine, said that there were signs that the Russian invasion had been prepared in advance, with Russia waiting for Georgia to fall in a trap and using the Georgian response as a pretext. Secretary of State for Foreign and Commonwealth Affairs David Miliband visited Ukraine in late August and told Ukrainians "not to provide any pretext" for Russia. He said, "The Russians have used those pretexts in the Georgian case and it's important to not repeat that." Georgian reintegration minister Temur Iakobashvili said, "The pilots we captured reported that they were mobilized days before Aug. 8.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.